Novo Nordisk sues pharmacies over impure Wegovy, Ozempic dupes

Novo Nordisk sues pharmacies over impure Wegovy, Ozempic dupes

A 0.25 mg injection pen of Novo Nordisk’s weight loss drug Wegovy is shown in this photo in Oslo, Norway, on Aug. 31, 2023. Victoria Klesty | Reuters Novo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and “potentially unsafe” drugs claiming to contain semaglutide, the active ingredient … Read more

Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly

Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced … Read more

Pfizer to discontinue twice-daily version of weight loss pill

Pfizer to discontinue twice-daily version of weight loss pill

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost significant weight but had trouble tolerating the drug in a mid-stage clinical study.  The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A … Read more

Pfizer weight loss pill joins list of obesity drug flops

Pfizer weight loss pill joins list of obesity drug flops

Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences.  The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug … Read more

Roche enters obesity market with Carmot takeover

Roche enters obesity market with Carmot takeover

BRAZIL – 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images) Sopa Images | Lightrocket | Getty Images Swiss pharmaceuticals giant Roche is set to acquire anti-obesity drug developer Carmot Therapeutics, becoming the … Read more

Eli Lilly weight loss drug Zepbound available at U.S. pharmacies

Eli Lilly weight loss drug Zepbound available at U.S. pharmacies

The FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy. Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues.  Zepbound … Read more

Biden administration asserts power to seize drug patents

Biden administration asserts power to seize drug patents

President Joe Biden speaks about protecting Social Security, Medicare, and lowering prescription drug costs, during a visit to OB Johnson Park and Community Center, in Hallandale Beach, Florida, on Nov. 1, 2022. Kevin Lamarque | Reuters The Biden administration on Thursday opened the door to seizing the patents of certain costly medications from drugmakers in … Read more

Wall Street analysts name 13 of our stocks as top picks for 2024

Wall Street analysts name 13 of our stocks as top picks for 2024

This year’s powerful rally has more than made up for the carnage of 2022 on Wall Street. Tech stocks reasserted their leadership and even some out-of-favor sectors perked up in recent weeks. So, what about 2024 for the market and our Club stocks? The Federal Reserve remains a big question as milder inflation data and … Read more

Health sector themes to watch in 2024

Health sector themes to watch in 2024

An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and … Read more

Patients on Eli Lilly drug regain weight after stopping it

Patients on Eli Lilly drug regain weight after stopping it

Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday.  The data, which represents the full results from an … Read more